Literature DB >> 20631311

CD30 discriminates heat shock protein 60-induced FOXP3+ CD4+ T cells with a regulatory phenotype.

Ismé de Kleer1, Yvonne Vercoulen, Mark Klein, Jenny Meerding, Salvatore Albani, Ruurd van der Zee, Birgit Sawitzki, Alf Hamann, Wietse Kuis, Berent Prakken.   

Abstract

In many animal models, the manifestations of inflammatory diseases can be prevented by the adoptive transfer of CD4(+)FOXP3(+) regulatory T cells (Tregs). CD4(+)FOXP3(+) Tregs can be obtained by isolation and expansion of polyclonal naturally occurring Tregs or by Ag-specific activation of CD4(+)CD25(-)FOXP3(-) T cells. Two major obstacles are hampering the translation of this latter protocol into therapeutic application. First, there is a lack of knowledge on relevant autoantigens. Second, the resulting population is contaminated with activated CD4(+) T cells that transiently express Forkhead box P3 but gain no regulatory function. Therefore, these cells may not be safe for clinical application. In this study, we demonstrate that highly suppressive FOXP3(+) Tregs can be induced in vitro by the activation of CD4(+)CD25(-) T cells with the self-Ag human 60-kDa heat shock protein (HSP60). The activation induced suppressive FOXP3(+) Tregs can be distinguished by surface expression of CD30 from nonsuppressive FOXP3(+) effector cells. We confirm that the induced CD30(+)FOXP3(+) Tregs recognize HSP60 epitopes and that the induction of Tregs by HSP60 is enhanced by signaling via TLR4 on APCs. These findings have implications for the generation and isolation of pure populations of Ag-specific Tregs, with the potential to prevent and treat human inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631311     DOI: 10.4049/jimmunol.0901901

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  High molecular weight stress proteins: Identification, cloning and utilisation in cancer immunotherapy.

Authors:  Xiang-Yang Wang; John R Subjeck
Journal:  Int J Hyperthermia       Date:  2013-07-05       Impact factor: 3.914

2.  Recognition of self-heat shock protein 60 by T cells from patients with atopic dermatitis.

Authors:  Berber Kapitein; Joost A Aalberse; Mark R Klein; Wilco de Jager; Maarten O Hoekstra; Edward F Knol; Berent J Prakken
Journal:  Cell Stress Chaperones       Date:  2012-08-07       Impact factor: 3.667

Review 3.  Heat shock protein bystander antigens for peptide immunotherapy in autoimmune disease.

Authors:  E Zonneveld-Huijssoon; S Albani; B J Prakken; F van Wijk
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

4.  Heat shock proteins, autoimmunity, and cancer treatment.

Authors:  Stuart K Calderwood; Mary Ann Stevenson; Ayesha Murshid
Journal:  Autoimmune Dis       Date:  2012-09-29

5.  Cord blood CD4+ T cells respond to self heat shock protein 60 (HSP60).

Authors:  Joost A Aalberse; Berber Kapitein; Sytze de Roock; Mark R Klein; Wilco de Jager; Ruurd van der Zee; Maarten O Hoekstra; Femke van Wijk; Berent J Prakken
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

6.  Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.

Authors:  Melissa G Lechner; Carolina Megiel; Sarah M Russell; Brigid Bingham; Nicholas Arger; Tammy Woo; Alan L Epstein
Journal:  J Transl Med       Date:  2011-06-09       Impact factor: 5.531

Review 7.  The effects of TLR activation on T-cell development and differentiation.

Authors:  Bo Jin; Tao Sun; Xiao-Hong Yu; Ying-Xiang Yang; Anthony E T Yeo
Journal:  Clin Dev Immunol       Date:  2012-06-07

8.  Heat shock proteins: conditional mediators of inflammation in tumor immunity.

Authors:  Stuart K Calderwood; Ayesha Murshid; Jianlin Gong
Journal:  Front Immunol       Date:  2012-04-09       Impact factor: 7.561

9.  Immune response markers in sentinel nodes may predict melanoma progression.

Authors:  Monica Rodolfo; Chiara Castelli; Licia Rivoltini
Journal:  Oncoimmunology       Date:  2014-04-15       Impact factor: 8.110

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.